Publication

[Zr-89]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer

van Helden, E. J., Elias, S. G., Gerritse, S. L., van Es, S. C., Boon, E., Huisman, M. C., van Grieken, N. C. T., Dekker, H., van Dongen, G. A. M. S., Vugts, D. J., Boellaard, R., van Herpen, C. M. L., de Vries, E. G. E., Oyen, W. J. G., Brouwers, A. H., Verheul, H. M. W., Hoekstra, O. S. & van Oordt, C. W. M. D. H., 9-Nov-2019, In : European Journal of Nuclear Medicine and Molecular Imaging. 47, p. 849-859 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • E. J. van Helden
  • S. G. Elias
  • S. L. Gerritse
  • S. C. van Es
  • E. Boon
  • M. C. Huisman
  • N. C. T. van Grieken
  • H. Dekker
  • G. A. M. S. van Dongen
  • D. J. Vugts
  • R. Boellaard
  • C. M. L. van Herpen
  • E. G. E. de Vries
  • W. J. G. Oyen
  • A. H. Brouwers
  • H. M. W. Verheul
  • O. S. Hoekstra
  • C. W. Menke-van der Houven van Oordt

Purpose One-third of patients with RAS wild-type mCRC do not benefit from anti-EGFR monoclonal antibodies. This might be a result of variable pharmacokinetics and insufficient tumor targeting. We evaluated cetuximab tumor accumulation on [Zr-89]Zr-cetuximab PET/CT as a potential predictive biomarker and determinant for an escalating dosing strategy. Patients and methods PET/CT imaging of [Zr-89]Zr-cetuximab (37 MBq/10 mg) after a therapeutic pre-dose (500 mg/m(2)

Original languageEnglish
Pages (from-to)849-859
Number of pages11
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume47
Publication statusE-pub ahead of print - 9-Nov-2019

    Keywords

  • Colorectal cancer, Targeted therapy, Cetuximab, Imaging biomarker, PET, CT, GROWTH-FACTOR RECEPTOR, EGFR EXPRESSION, PHASE-I, TUMOR, PHARMACOKINETICS, METAANALYSIS, PROGNOSIS, SURVIVAL, BENEFIT

Download statistics

No data available

ID: 107589950